Advertisement
SI-BONE, Inc.

SI-BONE, Inc. Fundamental Analysis

SIBNNASDAQ
HealthcareMedical - Devices
$15.31
$0.34(2.30%)
U.S. Market is Open · 12:20
Advertisement

SI-BONE, Inc. Fundamental Analysis

SI-BONE, Inc. (SIBN) shows weak financial fundamentals with a PE ratio of -40.46, profit margin of -8.10%, and ROE of -9.56%. The company generates $0.2B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position21.19%
PEG Ratio-0.73
Current Ratio9.99

Areas of Concern

ROE-9.56%
Operating Margin-9.67%
We analyze SIBN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 17.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
17.2/100

We analyze SIBN's fundamental strength across five key dimensions:

Efficiency Score

Weak

SIBN struggles to generate sufficient returns from assets.

ROA > 10%
-6.88%

Valuation Score

Excellent

SIBN trades at attractive valuation levels.

PE < 25
-40.46
PEG Ratio < 2
-0.73

Growth Score

Weak

SIBN faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

SIBN maintains a strong and stable balance sheet.

Debt/Equity < 1
0.04
Current Ratio > 1
9.99

Profitability Score

Weak

SIBN struggles to sustain strong margins.

ROE > 15%
-955.73%
Net Margin ≥ 15%
-8.10%
Positive Free Cash Flow
No

Key Financial Metrics

Is SIBN Expensive or Cheap?

P/E Ratio

SIBN trades at -40.46 times earnings. This suggests potential undervaluation.

-40.46

PEG Ratio

When adjusting for growth, SIBN's PEG of -0.73 indicates potential undervaluation.

-0.73

Price to Book

The market values SI-BONE, Inc. at 3.78 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.78

EV/EBITDA

Enterprise value stands at -96.44 times EBITDA. This is generally considered low.

-96.44

How Well Does SIBN Make Money?

Net Profit Margin

For every $100 in sales, SI-BONE, Inc. keeps $-8.10 as profit after all expenses.

-8.10%

Operating Margin

Core operations generate -9.67 in profit for every $100 in revenue, before interest and taxes.

-9.67%

ROE

Management delivers $-9.56 in profit for every $100 of shareholder equity.

-9.56%

ROA

SI-BONE, Inc. generates $-6.88 in profit for every $100 in assets, demonstrating efficient asset deployment.

-6.88%

Following the Money - Real Cash Generation

Operating Cash Flow

SI-BONE, Inc. generates limited operating cash flow of $1.89M, signaling weaker underlying cash strength.

$1.89M

Free Cash Flow

SI-BONE, Inc. generates weak or negative free cash flow of $-5.59M, restricting financial flexibility.

$-5.59M

FCF Per Share

Each share generates $-0.13 in free cash annually.

$-0.13

FCF Yield

SIBN converts -0.81% of its market value into free cash.

-0.81%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-40.46

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.73

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.78

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.31

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.04

vs 25 benchmark

Current Ratio

Current assets to current liabilities

9.99

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.10

vs 25 benchmark

ROA

Return on assets percentage

-0.07

vs 25 benchmark

ROCE

Return on capital employed

-0.09

vs 25 benchmark

How SIBN Stacks Against Its Sector Peers

MetricSIBN ValueSector AveragePerformance
P/E Ratio-40.4634.27 Better (Cheaper)
ROE-9.56%377.00% Weak
Net Margin-8.10%-42945.00% (disorted) Weak
Debt/Equity0.040.78 Strong (Low Leverage)
Current Ratio9.995.54 Strong Liquidity
ROA-6.88%-162.00% (disorted) Weak

SIBN outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews SI-BONE, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ